【C.S Group】: Antcin A and Steroid Combination Shows Synergistic Potential in Preliminary Study
TAIPEI, March 14, 2025 /PRNewswire/ -- Cordyceps Sunshine Biotech Holdings Co., Ltd. 【C.S Group】, in collaboration with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA), hosted the "Pharmacological Applications of Taiwanofungus Camphoratus in the Pet Market" Seminar in Taipei. During the event, 【C.S Group】 officially announced its latest research findings, revealing that Antcin A, a purified extract from Taiwanofungus camphoratus, demonstrates potential synergistic effects with traditional steroids.
The company is also exploring partnerships with premium pet food brands in China and plans to introduce exclusively supplied Taiwanofungus camphoratus extracts through its Greater China distributor, Guangdong Baoquan Agricultural Biotechnology, as part of its strategy to expand into the high-end pet food market.
Accelerating Commercialization of Taiwanofungus Camphoratus-Based Pharmaceuticals
Dr. Jia-Xin Huang, a leading expert in Taiwanofungus camphoratus, emphasized that developing new biopharmaceuticals traditionally requires extensive investment in animal and human trials, with no guarantee of success. However, Taiwanofungus camphoratus has already been extensively researched, providing a strong scientific foundation without needing to start from scratch.
A key concern in previous discussions has been the long-term use of traditional steroids, which often leads to liver and kidney damage as a side effect. Taiwanofungus camphoratus is known for its liver- and kidney-protective properties, prompting further studies into its potential to reduce the adverse effects of steroids without compromising efficacy.
To validate this hypothesis, 【C.S Group】 conducted an experiment combining its proprietary TF-15 Taiwanofungus camphoratus extract with the steroid dexamethasone (DXMS) in lung cancer cell models. The study confirmed:
Recognizing the regulatory and commercialization advantages of veterinary applications, 【C.S Group】 is prioritizing preclinical trials for pet medicine. The strategy includes:
- Establishing safe dosage and formulations for pets, such as oral solutions and chewable tablets.
- Accelerating human clinical trials by leveraging veterinary data.
- Expanding applications to both pet and human nutraceuticals, providing a flexible market strategy.
This approach offers a balanced and strategic entry into the pharmaceutical sector, positioning Taiwanofungus camphoratus as a viable candidate for integrated pet and human health solutions.
Vincent Liu, Chief Technology Officer at 【C.S Group】, highlighted the significant growth potential in China's pet market. As of 2024, China's pet population reached 124.1 million, with the pet food industry valued at $22.2 billion—including $9.8 billion in cat food and $10.3 billion in dog food. While mature markets like North America and Europe have penetration rates exceeding 90%, China's market penetration is still around 20%, signaling substantial room for growth.
According to the China Feed Industry Association (CFIA), there are approximately 200 certified pet food manufacturers in China, with a total annual production capacity of 1.12 million tons. The market is shifting towards premium branding, creating opportunities for high-end functional pet foods. 【C.S Group】 is actively engaging with China's leading premium pet food brands and, through its Greater China distributor, Guangdong Baoquan Agricultural Biotechnology, plans to integrate Taiwanofungus camphoratus extracts into premium pet food formulations.
Beyond pet nutrition, veterinary pharmaceuticals present another growth avenue. The global pet pharmaceutical market includes treatments for external and internal parasites, allergic dermatitis, anti-inflammatory pain relief, anti-nausea, insulin, antibiotics, and heart failure management. Given the broad-spectrum bioactivity of Taiwanofungus camphoratus, its potential therapeutic applications in pet medicine are highly promising.
Leading the Market with Antcin A Mass ProductionDalan Huang, President of 【C.S Group】, emphasized the importance of high-quality cultivation in ensuring premium product yields. He highlighted the company's commitment to optimizing Taiwanofungus camphoratus strain selection and mass production, enabling efficient extraction and purification of bioactive compounds for pharmaceutical applications.
"The efficacy of Antcin A is well established in the industry, but the real question is: who has the capability to lead the market in large-scale extraction and production?" Huang stated. "Whoever masters the mass production of Taiwanofungus camphoratus extracts will control the next phase of the industry."
While the company has ambitious goals, Huang stressed the importance of achievable milestones. Based on Dr. Jia-Xin Huang's preliminary findings, 【C.S Group】 has already made exciting progress and is optimistic that further optimization will lead to the development of the first batch of Taiwanofungus camphoratus-based veterinary pharmaceuticals. This breakthrough has the potential to accelerate commercialization and integration into the pet health industry.
With scientific validation, strategic partnerships, and market positioning, 【C.S Group】 is advancing Taiwanofungus camphoratus from traditional applications to next-generation pharmaceuticals. As the global pet and human health industries continue to expand, the company is well-positioned to lead innovation in functional ingredients and biopharmaceutical applications.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cs-group-antcin-a-and-steroid-combination-shows-synergistic-potential-in-preliminary-study-302401048.html
SOURCE Cordyceps Sunshine